title: Nodular melanoma arising in a patient treated with anti-tumor necrosis factor alpha antagonists.
authors.affiliation: University of Rome Sapienza, Rome, Italy.
authors.forename: Marta
authors.initials: M
authors.lastname: Carlesimo
authors.forename: Mauro
authors.initials: M
authors.lastname: La Pietra
authors.forename: Annalisa
authors.initials: A
authors.lastname: Arcese
authors.forename: Pier Paolo
authors.initials: PP
authors.lastname: Di Russo
authors.forename: Elena
authors.initials: E
authors.lastname: Mari
authors.forename: Amelia
authors.initials: A
authors.lastname: Gamba
authors.forename: Diego
authors.initials: D
authors.lastname: Orsini
authors.forename: Germana
authors.initials: G
authors.lastname: Camplone
mesh_terms: D017255:Acitretin / Q000009:adverse effects / Q000627:therapeutic use; D000068879:Adalimumab; D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000627:therapeutic use; D016572:Cyclosporine / Q000009:adverse effects / Q000627:therapeutic use; D003879:Dermatologic Agents / Q000627:therapeutic use; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000069285:Infliximab; D008297:Male; D008545:Melanoma / Q000175:diagnosis* / Q000209:etiology* / Q000473:pathology; D008727:Methotrexate / Q000627:therapeutic use; D011565:Psoriasis / Q000188:drug therapy; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D012720:Severity of Illness Index; D012878:Skin Neoplasms / Q000175:diagnosis* / Q000209:etiology* / Q000473:pathology; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D003879:Dermatologic Agents; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D016572:Cyclosporine; D000069285:Infliximab; D000068879:Adalimumab; D017255:Acitretin; D000068800:Etanercept; D008727:Methotrexate